Rho kinase inhibitor - Bayer
Latest Information Update: 01 Jul 2003
At a glance
- Originator Bayer
- Class Small molecules
- Mechanism of Action Rho-associated kinase inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 16 Jul 2001 Preclinical development for Cancer (Unknown route)